Next steps with 1% tenofovir microbicide gel
24 November 2010
After nearly 20 years of research, the results of the CAPRISA 004 trial provided the first evidence that the use of a vaginal microbicide could provide a safe and effective way to prevent HIV infection in women.
Following results from a South African study (CAPRISA 004) showing that a vaginal microbicide gel containing the antiretroviral drug tenofovir was 39% effective in reducing a woman’s risk of becoming infected with HIV during sex, WHO and UNAIDS convened a meeting in August 2010, just a month following the announcement, to review the implications of the CAPRISA 004 results and determine the appropriate next steps.
The meeting participants agreed on the below priority actions for follow-up:
- Additional safety studies;
- Effectiveness trial in South Africa to confirm the CAPRISA 004 BAT 24 dosing regimen;
- Effectiveness and safety trial of simplified dosing and HIV testing schedules;
- Implementation study in South Africa; and,
- Treatment outcome and resistance study.
Related feature storiesTaking the pulse: WHO global update on the HIV health sector response
20 July 2014Eliminating tuberculosis deaths: time to step up the HIV response
20 July 2014Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations
11 July 2014
- Next Steps with 1% Tenofovir Gel (pdf, 480 Kb.) (November 2010)
- Executive Summary (pdf, 128 Kb.) (November 2010)